BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMhance
- Sponsors AbbVie; Boehringer Ingelheim
- 05 Oct 2017 Planned End Date changed from 27 Jul 2018 to 3 Aug 2018.
- 31 Jan 2017 Planned End Date changed from 1 Jun 2018 to 27 Jul 2018.
- 04 Aug 2016 Status changed from recruiting to active, no longer recruiting.